Monday, July 8, 2002

• The Global Impact of the HIV/AIDS Epidemic
  Coverage by Pablo Tebas, M.D.
  
  • Prospects for the Eradication or Long-Term Control of HIV Infection (MoOr103)

• Treatment: Strategies for Lowering Prices
  Coverage by Keith Henry, M.D.
  
  • The Creation of a Non-Voluntary Patent Pool for Essential HIV Inventions (MoOrG108)
  Coverage by Pablo Tebas, M.D.
  
  • From Marrakech to Doha: Some Reflections on the Foundations of Patent Regime in Pharmaceutical Industry (MoOrG1035a)

• Positively Pregnant: HIV-Positive Women and Pregnancy
  Coverage by Judith A. Aberg, M.D.
  
  • You Can Even Possibly Have a Child: Reproduction in the Lives of HIV-Positive Women (MoOrE1067)
  • Intrauterine Insemination in HIV-Serodiscordant Couple for Male HIV Infection (MoOrE1070)

• Pharmacology and Drug Interactions
  Coverage by Andrew T. Pavia, M.D.
  
  • Decreased Plasma Concentrations of Amprenavir and Lopinavir in HIV Patients on This Combination (MoPpB2009)

• Retrospective Analysis of Tenofovir DF Use
  Coverage by Calvin J. Cohen, M.D., M.S.
  
  • Retrospective Analysis of the Use of Tenofovir DF in a Private Practice (MoPeA3005)

• Post-Exposure Prophylaxis Adherence
  Coverage by Benjamin Young, M.D., Ph.D.
  
  • Adherence to AZT/3TC (Combivir) as Post-Exposure Prophylaxis in Non-Occupational HIV Exposures (MoPeD3694)

Tuesday, July 9, 2002

• When Should You Start ARV Therapy?
  Coverage by Pablo Tebas, M.D.
  
  • When to Start ARV Therapy: Where Are We Now? (TuOrB148)

• Initial Therapy
  Coverage by Andrew T. Pavia, M.D.
  
  • Abacavir/Lamivudine (ABC/3TC) in Combination With Efavirenz (NNRTI), Amprenavir/Ritonavir (PI) or Stavudine (NRTI): ESS40001 (CLASS) Preliminary 48-Week Results (TuOrB1189)

• From Basic Science to Real Life: Disturbing Metabolic Disturbances
  Coverage by Mark Holodniy, M.D., F.A.C.P., C.I.C.
  
  • Basic Science and Metabolic Disturbances (TuOr158)
  • Clinical Impact (TuOr159)
  • It's Disturbing (TuOr160)

• Tipranavir as Rescue Therapy
  Coverage by Keith Henry, M.D.
  
  • Tipranavir/Ritonavir: Derivation of Doses That Achieve Effective Plasma Concentrations Above the IC50 for Multiple PI-Resistant HIV-1 Viruses (TuPeB4437)

• Liver Toxicity and HAART
  Coverage by Benjamin Young, M.D., Ph.D.
  
  • Low Incidence of Grade III/IV Hepatotoxicity in First HAART: Observations From 1,100 Patients Followed for 1 Year (TuPeB4534)

• Tenofovir Clinical Trial -- Antiretroviral Naive
  Coverage by Benjamin Young, M.D., Ph.D.
  
  • Efficacy of Tenofovir DF (TDF) Monotherapy in Chronically HIV-1 Infected Antiretroviral Treatment-Naive Patients (TuPeB4451)

• Durability and Tolerability of ABC/AZT/3TC
  Coverage by Keith Henry, M.D.
  
  • Durability and Tolerability of the Triple NRTI Regimen Abacavir/Zidovudine/Lamivudine (ABC/AZT/3TC) Based on Therapy Changes in Antiretroviral Therapy-Naive Patients in the Frankfurt HIV Cohort (TuPeB4453)

• Overall Tenofovir Safety Profile
  Coverage by Andrew T. Pavia, M.D.
  
  • Safety Profile of Tenofovir DF (TDF) in Antiretroviral Treatment-Experienced Patients From Randomized, Double-Blind, Placebo-Controlled Clinical Trials (TuPeB4460)

• Successful Intensification of Antiretroviral Therapy With Abacavir
  Coverage by Andrew T. Pavia, M.D.
  
  • Successful Intensification of Antiretroviral Therapy (ART) With Abacavir (ABC) in Clinical Practice (TuPeB4462)

• Clinical Trials -- Antiretroviral Experienced
  Coverage by Edwin DeJesus, M.D.
  
  • Efficacy and Safety of Amprenavir (APV)/Ritonavir (RTV) 600/100 mg BID Compared to APV 1,200 mg BID in ART-Experienced and Naive Subjects: ESS40011 (TuPeB4463)

• Rescue Therapy
  Coverage by Edwin DeJesus, M.D.
  
  • Phenotypic and Genotypic Profiles Predict Week 24 Responses to an Abacavir-Containing Salvage Regimen (TuPeB4479)

• Mitochondrial Toxicity Assays
  Coverage by Keith Henry, M.D.
  
  • Quantification of Mitochondrial DNA in Human Cells Using Real-Time PCR With Fluorogenic Reporters (TuPeB4509)

• Clinical Trials -- Antiretroviral Naive
  Coverage by Benjamin Young, M.D., Ph.D.
  
  • Zidovudine and Lamivudine (ZDV/3TC) Seminal Plasma:Blood Plasma (SP:BP) Concentration Ratios Do Not Predict Total SP Exposure (TuPeB4553)

• Pharmacology/Drug Interactions/Therapeutic Drug Monitoring
  Coverage by Keith Henry, M.D.
  
  • Preliminary Results of Intensification Therapy With Amprenavir (APV)/Ritonavir (RTV) in Two Different Doses: 1,200 (APV)/200 (RTV) QD vs. 600 (APV)/100 (RTV) BID in Heavily Pretreated Patients Failing HAART (TuPeB4580)
  Coverage by Benjamin Young, M.D., Ph.D.
  
  • Effective Plasma Levels of Amprenavir in Highly Challenging, Naive HIV Patients Following a Once-Daily HAART Regimen (TuPeB4556)
  • Directly Observed Therapy (DOT) in HIV: Is It Feasible in Clinical Practice? Problems Associated With DOT and an Amprenavir-Containing HAART Regimen in Antiretroviral-Naive Inner-City Minority Patients With Poor HIV Knowledge and Very Advanced AIDS (TuPeE5208)

• Drug Resistance
  Coverage by Mark Holodniy, M.D., F.A.C.P., C.I.C.
  
  • Prevalence of Genotypic Drug Resistance in HIV-Infected Individuals in New York State: The Resistance Study (TuPeB4584)
  Coverage by Edwin DeJesus, M.D.
  
  • High Incidence of Primary NNRTI Mutations and M184V in Isolates From Therapy-Experienced Adults Entering the ZORRO Trial (TuPeB4585)
  Coverage by Andrew T. Pavia, M.D.
  
  • Resistance Profiles at Baseline and Following Virologic Failure for Subjects Randomized to Receive Abacavir (ABC)/Efavirenz (EFV)/Didanosine (ddI) +/-; Hydroxyurea (HU) After Failing Initial NRTI +/- PI Therapy (TuPeB4587)

• Initiation of Therapy/When to Start
  Coverage by Pablo Tebas, M.D.
  
  • When to Start HAART: Evidence to Support Initiating Therapy at CD4+ Lymphocyte Counts <350 Cells/mm³ (TuPeB4661)
  • In Routine Practice, the Durability of First-Line HAART Is Better for NNRTI Than PI-Based Regimens, Regardless of Baseline HIV Status (TuPeB4673)

Wednesday, July 10, 2002

• Antiretroviral Therapy Issues in Experienced Patients
  Coverage by Judith A. Aberg, M.D.
  
  • Switching Protease Inhibitors to Nevirapine (NEV), Efavirenz (EFV) or Abacavir (ABA): A Randomized, Multicenter, Open-Label, Simplification Trial (WeOrB1262)
  Coverage by Calvin J. Cohen, M.D., M.S.
  
  • Tenofovir DF: A 48-Week Final Analysis From a Phase III Randomized, Double Blind, Placebo Controlled Study in Antiretroviral Treatment-Experienced Patients (Study 907) (WeOrB1266)

• Immune Response to HIV
  Coverage by Keith Henry, M.D.
  
  • Harnessing the Immune System to Fight HIV Infection (WeOrA197)
  • Immune Responses in Long-Term Non-Progressors -- Lessons for Immune Reconstitution (WeOrA199)

• Emerging Toxicity of Antiretoviral Therapy
  Coverage by Pablo Tebas, M.D.
  
  • Fat Redistribution and Metabolic Changes With a Nucleoside-Reverse Transcriptase Inhibitor (NRTI), Non-NRTI, or Protease Inhibitor-Based Regimen: FRAMS Substudy of the Atlantic Study (WeOrB1306)
  Coverage by Mark Holodniy, M.D., F.A.C.P., C.I.C.
  
  • Perspective of HIV-Associated Coronary Heart Disease (WeOrB203)

• Pharmacology/Drug Interactions/Therapeutic Drug Monitoring
  Coverage by Benjamin Young, M.D., Ph.D.
  
  • Antiviral Potency and Tolerability of a Convenient Once-a-Day Directly Observed Therapy With an Amprenavir-Containing HAART Regimen in Antiretroviral Naive, Inner-City Minority Patients With Poor HIV Knowledge and Very Advanced AIDS (WePeB5899)

• Women and Pregnancy
  Coverage by Andrew T. Pavia, M.D.
  
  • Abacavir Use in HIV-Positive Pregnant Women (WePeB5909)

• Tenofovir Use in HIV/HBV Co-Infection
  Coverage by Andrew T. Pavia, M.D.
  
  • Anti-Hepatitis B Virus (HBV) Activity of Tenofovir Disoproxil Fumarate (TDF) in Lamivudine (LAM) Experienced HIV/HBV Co-Infected Patients (WePeB6015)

• Virologic and Immunologic Markers of Disease Progression
  Coverage by Edwin DeJesus, M.D.
  
  • A Synergistic Effect of HIV and CMV Infection/Reactivation on Response to HAART and Plasma CD8+/CD38+ But Not CD4+ Cell Populations in Patients With Primary HIV Infection (WePeC6235)

• Long-Term Adverse Effects of Antiretroviral Therapy
  Coverage by Benjamin Young, M.D., Ph.D.
  
  • Simplification of Protease Inhibitor (PI)-Based Highly Active Antiretroviral Regimens With Abacavir (ABC) Improves Hyperlipidemia and Maintains Viral Suppression in HIV-1-Infected Adults (ESS40003) (WePeC6267)

• Interventions and MTCT Program Implementation
  Coverage by Judith A. Aberg, M.D.
  
  • Promoting Prevention of Mother-to-Child Transmission of HIV Through the Viramune Donation Programme: A Model of Public-Private Partnership (WePeF6673)

Thursday, July 11, 2002

• HIV Pathogenesis
  Coverage by Keith Henry, M.D.
  
  • HIV-1 Superinfection: AE Subtype Supplanted by B Subtype (ThOrA1381)

• Antiretroviral Drug Resistance
  Coverage by Mark Holodniy, M.D., F.A.C.P., C.I.C.
  
  • The GUESS Study: An International Evaluation of the Accuracy, Precision and Consistency of Expert HIV-1 Genotype Interpretation (ThOrB1385)
  • Genotypic (GT) and Virtual Phenotypic (vPT) Correlates of Virologic Response to Abacavir (ABC)-Based Therapy in the ZORRO Trial (ESS40009) (ThOrB1386)
  • The Clinical Relevance of Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) Hypersusceptibility: A Prospective Cohort Analysis (ThOrB1388)
  • Expanded Response Analyses of Tenofovir DF Therapy by Baseline Resistance Genotype and Phenotype (ThOrB1390)

• Morbidity and Mortality Patterns in the HAART Era
  Coverage by Paul E. Sax, M.D.
  
  • Continued Benefit From Highly Active Antiretroviral Therapy: Trends in AIDS-Related Opportunistic Illnesses in a Public Health Care System, 1990-2001 (ThOrC1443)

• Treatment Interruption
  Coverage by Calvin J. Cohen, M.D., M.S.
  
  • Treatment Interruption in Primary HIV Infection (ThOrB260)
  • Treatment Interruption in Chronic HIV Infection (ThOrB261)
  • Treatment Interruption in Salvage Therapy (ThOrB263)
  • Structured Treatment Interruptions (STI) in Patients Receiving HAART Within 90 Days After Onset of Primary HIV-1 Infection (PHI) Symptoms: Spontaneous Control of Viremia in Only One Third of Cases After Four Cycles Off Therapy (ThOrB1437)
  • Prolonged Treatment Interruption After Immunologic Response to HAART (ThOrB1439)
  • Treatment Discontinuation in Patients Who Started Antiretroviral Therapy Following the 1996 IAS-U.S.A. Recommendations. A Prospective Randomized Trial (ThOrB1440)
  Coverage by Paul E. Sax, M.D.
  
  • Dynamics of Viral Rebound in Plasma and Semen After Stopping Effective Antiretroviral Therapy (ThOrB1441)

• Immunity and Immune Reconstitution
  Coverage by Keith Henry, M.D.
  
  • Evaluation of Immune Restoration Parameters in Antiretroviral Therapy (ART)-Naive Patients: Role of the Thymus in Naive T Cell Rise (COLA3003 Study) (ThPpA2129)

• Viral, Immunological and Clinical Features
  Coverage by Keith Henry, M.D.
  
  • Relationship of Immunological Markers and Thymic Index to CD4+ T Cells and HIV RNA at Baseline in Treatment Naive HIV-Infected Patients (ThPeB7177)

• Clinical Sciences and Care
  Coverage by Paul E. Sax, M.D.
  
  • A Prospective, Multicenter, Randomized Trial Comparing the Efficacy and Safety of Fenofibrate Versus Pravastatin in HIV-Infected Subjects With Lipid Abnormalities (ACTG 5087) (LbPeB9018)
  • Strategies to Prevent Loss of CD4+ and Onset of Resistance During Treatment Interruptions (LbPeB9025)
  Coverage by Keith Henry, M.D.
  
  • Is Simplification to Triple Antiretroviral Therapy After Viral Suppression With Quadruple Therapy Initiated at the Time of Primary Infection Associated With Increased Low-Level Viral Breakthrough? (ThPeB7207)
  • Pharmacodynamic Effects of Zidovudine 600 mg Once Daily Versus Zidovudine 300 mg Twice Daily in Therapy-Naive HIV-Infected Patients (COD20002) (LbPeB9020)
  Coverage by Pablo Tebas, M.D.
  
  • Metabolic and Body Composition Changes in Patients Switching From a Protease Inhibitor-Containing Regimen to Abacavir (ABC), Efavirenz (EFV) or Nevirapine (NVP). Twelve-Month Results of a Randomized Study (LIPNEFA) (ThPeB7354)
  Coverage by Robert J. Frascino, M.D.
  
  • Once-Weekly Epoetin Alfa Corrects Hemoglobin and Improves Quality of Life as Effectively as Three-Times Weekly Dosing in HIV-Positive Patients (ThPeB7381)
  Coverage by Benjamin Young, M.D., Ph.D.
  
  • Tenofovir DF (TDF) and Didanosine EC (ddI EC): Investigation of Pharmacokinetic (PK) Drug-Drug and Drug-Food Interactions (LbPeB9026)

• Early Diagnosis, Prophylaxis and Treatment of Opportunistic Infections
  Coverage by Benjamin Young, M.D., Ph.D.
  
  • Embrace: A Collaborative Approach to HIV Health Promotion for African Communities in the U.K. (ThPeF8218)

• Importance of Early HAART Initiation
  Coverage by Judith A. Aberg, M.D.
  
  • Earlier Initiation of HAART Better Preserves Functional Immune Competence Even in Persons Who Achieve "Normal" CD4+ T-Cell Counts (LbOr09)

Friday, July 12, 2002

• Initial Antiretroviral Therapy
  Coverage by Calvin J. Cohen, M.D., M.S.
  
  • Efficacy and Safety of Tenofovir Disoproxil Fumarate (TDF) Versus Stavudine (d4T) When Used in Combination With Lamivudine (3TC) and Efavirenz (EFV) in HIV-1 Infected Patients Naive to Antiretroviral Therapy (ART): 48-Week Interim Results (LbOr17)
  Coverage by Pablo Tebas, M.D.
  
  • Antiretroviral Strategies in Naive HIV-Positive Subjects: Comparison of Sequential Three-Drug Regimens (ACTG 384) (LbOr20A)
  • Antiretroviral Strategies in Naive HIV-Positive Subjects: Comparison of Four-Drug Versus Sequential Three-Drug Regimens (ACTG 384) (LbOr20B)

• T-20 as Rescue Therapy
  Coverage by Pablo Tebas, M.D.
  
  • Enfuvirtide (T-20) in Combination With an Optimized Background (OB) Regimen vs. OB Alone in Patients With Prior Experience or Resistance to Each of the Three Classes of Approved Antiretrovirals (ARVs) in Europe and Australia (LbOr19A)
  • Enfuvirtide (T-20) in Combination With an Optimized Background (OB) Regimen vs. OB Alone in Patients With Prior Experience or Resistance to Each of the Three Classes of Approved Antiretrovirals (ARVs) in North America and Brazil (LbOr19B)

• HAART and Anal Neoplasia
  Coverage by Judith A. Aberg, M.D.
  
  • Effect of HAART on Incidence of Anal Intraepithelial Neoplasia Grade 3 Among HIV-Positive Men Who Have Sex With Men (LbOr21)

• Prevention of Perinatal HIV Transmission
  Coverage by Judith A. Aberg, M.D.
  
  • Nevirapine (NVP) During Labor and in the Neonate Significantly Improves Zidovudine (ZDV) Prophylaxis for the Prevention of Perinatal HIV Transmission: Results of PHPT-2 First Interim Analysis (LbOr22)

Saturday, July 13, 2002

• Overviews
  Coverage by Pablo Tebas, M.D.
  
  • A Roundup of Barcelona
  Coverage by Myles Helfand
  
  • Adherence Research Roundup From the International AIDS Conference
  Coverage by Barbara Jungwirth
  
  • Highlights of Presentations on Gender From Barcelona

  
  

  Return to The Body's coverage of
  The XIV International AIDS Conference.